Sonoma Pharmaceuticals Announces Expansion of its Oral Products Partner Network in the United States and China


WOODSTOCK, Ga.–(BUSINESS WIRE)–Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented stabilized hypochlorous acid (HOCl) products based on Microcyn® technology for a wide range of applications, including including wound care, eye, mouth and nose care, disinfectant use and skin conditions, today announced that it has added Salus Medical as an additional U.S. distribution partner for dental care and expanded its oral care ranges to China via a partnership agreement with Anlicare International.

Sonoma has entered into a non-exclusive agreement with Salus Medical to distribute Endocyn® Root Canal Irrigator through their existing dental canals. Additionally, Salus Medical will expand its cutting-edge dermatology offerings with Sonoma’s Microcyn® RX and Regenacyn® Plus products and will have non-exclusive distribution rights for Microcyn® wound care products.

“We believe Endocyn Root Canal Irrigator will be a great addition to our product portfolio at Salus Medical. Endocyn and the Microcyn product line align with our strategy of being dedicated to bringing value to the healthcare system. American while combining quality and economy,” said Hernan Alvarez, president of Salus Medical.

Additionally, on January 18, 2022, Sonoma and Anlicare agreed to cooperate to complete the regulatory work necessary to obtain licenses in China to distribute Sonoma’s dental and oral products based on Microcyn® technology. Anlicare will bear the regulatory costs and in return Sonoma has agreed to grant Anlicare exclusive rights to sell and distribute oral care products in China.

“We see the strength of Sonoma’s Microcyn technology in preventing infection and reducing bacteria and microorganisms and believe that Sonoma’s Microcyn technology will benefit dentistry and general oral care for professional use. and general public,” commented Sherwin Hu, CEO of Anlicare International. .

“We are delighted to add Salus Medical and Anlicare to our growing network of distributors for our oral products, and we continue to seek distribution partners for our proprietary Microcyn technology which is truly superior in terms of antimicrobial impact, shelf stability and safety,” said Bruce Thornton, chief operating officer of Sonoma Pharmaceuticals.

About Salus Medical

Since 2012, Salus Medical has been a national wholesaler based in Phoenix, Arizona. As a generic wholesaler or distributor of generic pharmaceuticals, Salus Medical has been focused on providing economy and value to its customers. Due to its focus on customer needs, Salus Medical has experienced phenomenal growth in its short history. As Salus Medical has grown over the years, it has formed strategic relationships with a wide variety of vendors nationwide, enabling Salus Medical to provide a low cost, yet high quality product line. By offering a broad product portfolio, Salus Medical is able to serve multiple medical facilities and providers across the healthcare continuum, including pharmacies, clinics, surgery centers and hospitals.

About Anliacare International

Founded in 2012, Anlicare International’s founders and management team hail from China’s top pharmaceutical companies and have decades of valuable experience in China’s pharmaceutical and medical device markets. Anlicare works closely with leading international medical companies and top medical clinical teams in China in various medical fields to bring and market innovative medical devices and consumables to the Chinese market.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, animal healthcare, eye care, nasal care, oral care, use of disinfectants and skin conditions. The company’s products reduce infection, itching, pain, scarring and harmful inflammatory responses safely and effectively. In vitro and clinical studies on hypochlorous acid (HOCl) show that it has impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itching and pain, kills pathogens and breaks down biofilm, won’t sting or irritate skin, and oxygenates cells in the treated area, aiding the body in its natural healing process . The company’s products are sold directly or through partners in 54 countries around the world and the company is actively seeking new distribution partners. The company’s main office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are based in Roermond, the Netherlands. More information can be found at For partnership opportunities, please contact

Forward-looking statements

Except for historical information contained in this press release, the matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about business and technological progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “continue”, “develop” and “expand”, among others. The forward-looking statements contained in this press release are subject to certain risks and uncertainties inherent in the business of doing business that could cause actual results to vary, including risks that clinical developments and regulatory guidelines may change, data scientific evidence may not be sufficient to meet regulatory standards or the receipt of required regulatory clearances or approvals, clinical results may not be replicated in real patient environments, the protection afforded by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the market available for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, the revenues will not be sufficient to meet the needs of tr business flow, fund further development, as well as uncertainties related to the COVID-19 pandemic and economic development, varied product formulations, and a multitude of regulations and marketing requirements in different countries and municipalities , and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Microcyn®, Endocyn® and Regenacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.


Comments are closed.